USS Investment Management Ltd Has $6.21 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

USS Investment Management Ltd trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 26,366 shares of the biopharmaceutical company's stock after selling 6,505 shares during the period. USS Investment Management Ltd's holdings in Alnylam Pharmaceuticals were worth $6,210,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Allworth Financial LP boosted its stake in Alnylam Pharmaceuticals by 6.8% in the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after buying an additional 38 shares during the last quarter. Investment Management Corp of Ontario raised its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after purchasing an additional 40 shares during the period. Nixon Peabody Trust Co. lifted its stake in shares of Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock valued at $540,000 after purchasing an additional 43 shares in the last quarter. Brevan Howard Capital Management LP lifted its stake in shares of Alnylam Pharmaceuticals by 3.4% in the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock valued at $314,000 after purchasing an additional 44 shares in the last quarter. Finally, IFP Advisors Inc lifted its stake in shares of Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 47 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ALNY has been the topic of several research analyst reports. Wells Fargo & Company lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. UBS Group lifted their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Citigroup lifted their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. Finally, William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Stock Down 0.7%

NASDAQ ALNY traded down $2.09 during trading hours on Wednesday, hitting $288.01. 470,020 shares of the company traded hands, compared to its average volume of 916,211. The business's 50-day moving average is $259.82 and its 200-day moving average is $254.53. Alnylam Pharmaceuticals, Inc. has a twelve month low of $146.79 and a twelve month high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market capitalization of $37.55 billion, a price-to-earnings ratio of -133.07 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same period last year, the firm posted ($0.16) earnings per share. The firm's revenue was up 20.2% on a year-over-year basis. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.